CRISPR-Select and other functional approaches can provide critical insights regarding the impact of mutations on clinically relevant properties of ERCC2 and other DNA repair proteins, and therefore may ultimately be helpful in guiding individualized treatment approaches for patients with bladder cancer or other tumor types. Here, ERCC2 is linked to urinary bladder carcinoma.